Atreca Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Good afternoon, and welcome once again to Cowen & Company's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate our fireside chat with Atreca. We have with us this afternoon, John Orwin, the Chief Executive Officer; Herb Cross, Chief Financial Officer; Tito Serafini, Chief Strategy Officer; Jonathan Benjamin, the SVP of Clinical Research. I believe Alex Gray from Investor Relations is also in the room.
Questions & Answers
John, maybe we'll start with you. Last time, you announced a corporate restructuring to extend your cash runway. Could you discuss how you have prioritized your spend and the impact that's going to have on your operational runway?
Yeah, thanks for the question, Phil. I think we found ourselves in a position where we have seen responses for ATRC-101, our clinical-stage
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |